Davide Francomano

Dr. Davide Francomano

Division of Internal Medicine and Endocrinology, Madonna delle Grazie Hospital, Velletri, Rome, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CMClaudio Manna
Claudio Manna
FBFederica Barbagallo
Federica Barbagallo
RMRaffaella Manzo
Raffaella Manzo
ARAshraf Rahman
Ashraf Rahman
Davide FrancomanoDavide Francomano
Davide Francomano
Aldo E. CalogeroAldo E. Calogero
Aldo E. Calogero
Background: Recent studies have supported the beneficial effects of a short abstinence period on sperm parameters. The aim of this study was to assess sperm motility, morphology and DNA fragmentation before and after swim-up of a second ejaculate obtained after a short abstinence period in normozoospermic men and oligo-astheno-teratozoospermic (OAT) patients. Material and methods: Semen analyses and swim-up preparations of two consecutive semen samples (collected within 1 h) were carried out in 30 normozoospermic and 35 OAT patients enrolled in an assisted reproductive technique (ART) program. Results: Compared to the first ejaculate, the second sample showed a higher percentage of spermatozoa with normal form (p < 0.01) and lower percentage of spermatozoa with DNA fragmentation (p < 0.01) in normozoospermic men, whereas a higher percentage of spermatozoa with progressive motility (p < 0.001) and normal morphology (p < 0.0001) was found in OAT patients. Swim-up separation showed a lower DNA fragmentation rate (p < 0.05) in the second ejaculate in normozoospermic men, whereas the second ejaculate of OAT patents showed an increase in normally-shaped spermatozoa (p < 0.01) and lower percentage of spermatozoa with fragmented DNA (p < 0.001) compared to the first one. Conclusions: Swim-up separation of a second ejaculate collected within 1 h might be suggested for ART procedures, especially in OAT patients.

Verified
Journal Article
Open access
PDF file
Davide FrancomanoDavide Francomano
Davide Francomano
VSValerio Sanguigni
Valerio Sanguigni
PCPaolo Capogrosso
Paolo Capogrosso
FDFederico Deho
Federico Deho
GAGabriele Antonini
Gabriele Antonini
Hormones and cytokines are known to regulate cellular functions in the testes. These biomolecules induce a broad spectrum of effects on various level of spermatogenesis, and among them is the modulation of cell junction restructuring between Sertoli cells and germ cells in the seminiferous epithelium. Cytokines and androgens are closely related, and both correct testicular development and the maintenance of spermatogenesis depend on their function. Cytokines also play a crucial role in the immune testicular system, activating and directing leucocytes across the endothelial barrier to the inflammatory site, as well as in increasing their adhesion to the vascular wall. The purpose of this review is to revise the most recent findings on molecular mechanisms that play a key role in male sexual function, focusing on three specific molecular patterns, namely, cytokines, miRNAs, and endothelial progenitor cells. Numerous reports on the interactions between the immune and endocrine systems can be found in the literature. However, there is not yet a multi-approach review of the literature underlying the role between molecular patterns and testicular and sexual function.

9 October 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
Marco MarchettiMarco Marchetti
Marco Marchetti
GCGiulia Campisano
Giulia Campisano
Rosa Maria ParagliolaRosa Maria Paragliola
Rosa Maria Paragliola
Davide FrancomanoDavide Francomano
Davide Francomano
VCValerio Cipolloni
Valerio Cipolloni
ACAlessandro Conforti
Alessandro Conforti
Background: Weight regain and loss of cardiometabolic benefit commonly follow the withdrawal of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists, yet maintenance strategies are incompletely characterized. Methods: We conducted a systematic review reported according to PRISMA 2020 of primary studies in adults with overweight or obesity, with or without type 2 diabetes. PubMed/MEDLINE, Europe PMC and ClinicalTrials.gov were searched from inception to September 2026, supplemented by backward/forward citation searching and cross-checking of recent systematic reviews. Eligible reports quantified weight or cardiometabolic outcomes at least 12 weeks after planned or unplanned treatment cessation, or tested a post-cessation maintenance strategy. Randomized reports were assessed with RoB 2 and non-randomized reports with ROBINS-I. Owing to incompatible estimands, follow-up schedules, cointerventions and overlapping trial families, results were synthesized narratively without a new pooled estimate. Results: Eighteen reports representing 16 study families were included. Randomized withdrawal trials showed renewed weight gain after treatment cessation: +6.9% over 48 weeks after switching from semaglutide to placebo in STEP 4, and +14.0% over 52 weeks after switching from tirzepatide to placebo in SURMOUNT-4. In the STEP 1 extension, participants regained 11.6 percentage points over one year, approximately two-thirds of their prior loss, while several cardiometabolic measures moved toward baseline. Real-world estimates were smaller and more variable because discontinuation was often inferred from prescriptions, follow-up weights were missing, and many patients restarted or switched therapy. Cardiometabolic rebound was associated with the degree of weight regain, but clinical cardiovascular events were not evaluated. Evidence for maintenance strategies was sparse: one randomized post-treatment study supported supervised exercise, with the exercise-plus-liraglutide group retaining an additional 5.1 kg of weight loss one year after both interventions ended compared with liraglutide alone; a small pilot supported sitagliptin plus metformin after liraglutide in polycystic ovary syndrome. No eligible controlled trial isolated a specific diet after cessation. Conclusions: Weight regain is frequent after stopping GLP-1-based therapy, although magnitude varies by drug, design, follow-up and subsequent treatment. Structured exercise may help reduce regain and preserve lean mass, but evidence for dietary, behavioral, tapering or pharmacologic transition strategies remains limited. Discontinuation should therefore be planned as part of chronic obesity care, with explicit monitoring and shared decision-making, rather than presented as a predictable short course.